新桥生物 NBP 深 沪
等待开盘 03-26 09:30:00 美东时间
2.64
+0.120
+4.76%
华盛通- 最 高2.77
- 今 开2.53
- 成交量 88.67万股
- 最 低 2.52
- 昨 收 2.52
- 总市值 3.04亿
- 52周最高 6.79
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 0.61
- 委 比 18.24%
- 总股本 1.15亿
- 历史最高 85.40
- 量 比 1.34
- 振 幅 9.92%
- 历史最低 0.595
- 每 手 1
- 风险率 1.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NovaBridge Biosciences CFO Lei Ming Kyler files initial beneficial ownership statement
NovaBridge Biosciences CFO Lei Ming Kyler files initial beneficial ownership statement NovaBridge Biosciences filed an initial statement of beneficial ownership naming Lei Ming Kyler as Chief Financial Officer. Lei Ming Kyler reported a 2025 Employee Share Option covering 996,775 ordinary shares. Th
03-19 09:40
NovaBridge Biosciences Director Fu Wei Files Initial Beneficial Ownership Statement
NovaBridge Biosciences Director Fu Wei Files Initial Beneficial Ownership Statement NovaBridge Biosciences reported an initial statement of beneficial ownership filed by Fu Wei, a director. The filing listed indirect holdings of 11,784,164 ordinary shares through CBC Investment l-Mab. It also report
03-19 09:38
NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement
NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement NovaBridge Biosciences reported that Emmett Cunningham filed an initial statement of beneficial ownership as a director. The filing disclosed a 2025 employee share option covering 120,000 shares with an ex
03-19 09:36
NovaBridge Biosciences Director Liu Xin Files Initial Beneficial Ownership Statement
NovaBridge Biosciences Director Liu Xin Files Initial Beneficial Ownership Statement NovaBridge Biosciences filed an initial statement of beneficial ownership on March 18, 2026. The filing lists Xin Liu as a director. The form states that no securities are beneficially owned by Xin Liu. Disclaimer:
03-19 09:35
NovaBridge Biosciences Director Woo Ian Ying Files Initial Beneficial Ownership Statement
NovaBridge Biosciences Director Woo Ian Ying Files Initial Beneficial Ownership Statement NovaBridge Biosciences reported that Ian Ying Woo filed an initial statement of beneficial ownership as a director, with the event date listed as 03/18/2026. The filing lists a 2025 employee share option coveri
03-19 09:31
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP) with a Buy and maintains $9 price target.
03-17 00:20
Analysts’ Top Healthcare Picks: Esperion (ESPR), NovaBridge Biosciences (NBP)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
03-16 23:50
NovaBridge plans Q4 2026 Phase 3 trial of givastomig in first-line gastric cancer
NovaBridge plans Q4 2026 Phase 3 trial of givastomig in first-line gastric cancer NovaBridge reported that the FDA provided alignment in a Type B meeting on the potential eligibility of givastomig for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer. Th
03-16 19:04
Biotech一哥，忍痛割肉
（来源：CHC医疗传媒） 2015年，全球第一个CD73单抗MEDI9447进入临床阶段，至此，肿瘤靶点界一颗新的rising star闪闪发光。但是十年过去了...
03-13 14:30
